Refractory Bone Marrow Involvement Responding to Ribociclib and Tamoxifen in Advanced Breast Cancer
- 11 Downloads
A 64-year-old female was presented with bicytopenia and was diagnosed with carcinoma left breast, cT3N1M1 (bone marrow/bone/pleural effusion/leptomeningeal involvement). Histopathology showed infiltrating ductal carcinoma, grade 3, and immunohistochemistry showed ER (estrogen receptor) 90%; PR (progesterone receptor) 60%; HER2 neu 2 + and FISH (fluorescent in situ hybridization) for HER2 neu was negative. As she had bicytopenia (hemoglobin 6.8 gm/dl and platelet count 50,000 cells/mm3), she was treated with Inj. cyclophosphamide 500 mg weekly twice for 1 week followed by weekly paclitaxel 80 mg/m2 and intrathecal methotrexate. After six cycles of weekly paclitaxel, her blood counts recovered (hemoglobin 8.9 gm/dl and platelet count 105,000 cell/mm3). After 11 cycles of weekly paclitaxel, she had fatigue and decreased albumin (serum albumin 2.3 mg/dl) and was switched to Tab. letrozole 2.5 mg OD. She was intolerant to letrozole with grade 3 musculoskeletal pain and was switched to Tab....
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 10.Cristofanilli M, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425–39.CrossRefGoogle Scholar